DSMB Clears BriaCell's Phase 3 Bria-ABC Study of Bria-IMT Plus Checkpoint Inhibitor for Seventh Straight Time
核心洞察
An independent Data Safety Monitoring Board found no safety or other clinical concerns in BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor (搜索).
The seventh consecutive positive DSMB recommendation supports continuation of the trial without modifications in patients with metastatic breast cancer (搜索).
The pivotal Phase 3 study is being conducted under FDA Fast Track designation, reflecting the substantial unmet medical need in metastatic breast cancer (搜索).
An independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation for BriaCell Therapeutics Corp. (搜索)'s pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor (搜索) (CPI) in patients with metastatic breast cancer (搜索) (NCT06072612), the company announced on Sept. 14, 2026.
Following its review of clinical data, the DSMB raised no safety or other clinical concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol.
The repeated positive recommendations reinforce the favorable safety and tolerability profile of BriaCell's novel immunotherapy approach, according to the company. BriaCell is a clinical-stage biotechnology company developing novel immunotherapies intended to transform cancer care.
Regulatory Status and Unmet Need
The ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (搜索) (FDA). According to the company, this designation reflects the significant unmet medical need in metastatic breast cancer (搜索).
Company Perspective
"We are very encouraged by the DSMB's seventh consecutive positive recommendation to continue BriaCell's pivotal Phase 3 Bria-ABC study," said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. "This milestone represents continued progress in developing BriaCell's novel immunotherapies for patients with urgent unmet medical needs."
Study Details at a Glance
The Bria-ABC trial is evaluating Bria-IMT in combination with an immune checkpoint inhibitor (搜索) in patients with metastatic breast cancer (搜索). The study is registered under identifier NCT06072612, and safety oversight is conducted through quarterly DSMB reviews as specified in the protocol. No efficacy data or additional endpoints were disclosed in the announcement.
BriaCell Therapeutics Corp. (搜索) trades on the Nasdaq under the symbols BCTX and BCTXL and on the Toronto Stock Exchange under BCT.